Blindness is one of the most feared health hazards in our present society; millions of Europeans are threatened by blinding, untreatable eye diseases producing costs of several billion Euros. The European Vision Institute (EVI) (www.europeanvisioninstitute.org) aims at devising and implementing programmes and projects for new therapeutic strategies for eye diseases that are difficult or impossible to be treated presently.
1 EVI's approach will incorporate the most recent scientific developments of the post-genomic area.
However, the explosion of technological advances, scientific efforts and opportunities to disseminate new knowledge in the last decade is placing healthcare professionals in a challenging position to keep abreast of current developments in science. Therefore, EVI should be of enormous strategic importance for the future and is targeted towards more immediate policy objectives of improving the visibility and competitiveness of European Vision Research (www.vision-research.eu).
EVI integrates, conducts and supports research that helps to prevent and treat eye diseases and other disorders of vision. This research leads to sight-saving treatments, reduces visual impairment and blindness and improves the quality of life for people of all ages. 2 To implement these targets it is necessary to accelerate and strengthen the clinical research process and to establish the infrastructure and organisation necessary to translate basic laboratory discoveries into the reality of improved patient care. This necessary process will indirectly increase the quality of life for many people in the EU. Therefore, it is mandatory to create the basis for more efficient and effective translational research, characterise clinical research policies among countries within the EU and harmonise and validate objective tests of disease progression and patient-reported outcomes. 
Pilot and Collaborative Translational and Clinical Studies
New resources are generally required to determine whether the clinical potential of a promising laboratory finding can be realised.
Such funds must be available promptly and be accompanied by an organisational structure that allows full compliance with regulatory requirements. Each centre or network of centres should be able to request support for pilot and collaborative clinical research projects that:
• allow clinical and translational trainees or researchers to generate preliminary data for submission of a research grant application;
• address clinical trial design, novel biostatistics approaches, informatics and regulatory pathways; and
• develop new technologies.
These pilot and collaborative projects should, in general, be of sufficient scope to qualify as a stand-alone research effort and should be well integrated into the activities of the centre. 
Development of Communication Pathways

Implementation of Investigator-driven Clinical Trials
It is well accepted that improving conditions for better IDCT and clinical research will translate into better patient care and health worldwide.
The top five recommendations to strengthen IDCT in Europe as ranked by a recent consensus conference as follows:
• to improve the education, training and career structure and opportunities for scientists involved in patient-orientated clinical research;
• to increase levels of funding for IDCT;
• to adopt a 'risk-based' approach to the regulation of IDCT;
• to streamline procedures for obtaining authorisation for IDCT; and
• to ensure that IDCT are carried out with an appropriate number of patients to produce statistically reliable results so that the trials are 'correctly powered'.
These directions are considered a fundamental step towards effective translational research and they include the need for one or more centralised facilities to support and co-ordinate the activities of transnational IDCT. 
Centralised Support for Research Design, Epidemiology, Biostatistics and Clinical Research Ethics
Clinical Research Networks
Because of the vast number of therapies, diagnostics and treatments that must be evaluated through clinical trials, many clinical research networks operate simultaneously, but independently, of each other.
As a result, researchers must sometimes duplicate data that already exist because they are unaware of, or do not have access to, the data. Standardising data reporting would enable seamless data-and sample-sharing across studies. By enhancing the efficiency of clinical research networks through informatics and other technologies, researchers will be able to more easily broaden the scope of their research. Reduced duplication of studies will leave more time and funds to address additional research questions.
Clinical Research Network Inventory
The goal of this effort is to determine best practices in clinical research networks by conducting an inventory of existing national networks.
This project examines organisational and management structures of existing networks and evaluates the types and volume of studies being conducted. Other parameters to be analysed include network performance, informatics infrastructure and training procedures.
Integrating Clinical Research Networks
This initiative will test the feasibility of integrating and expanding existing clinical research networks. A particular focus is on assessing the capacity for interoperability among networks. This will broaden the kinds of research questions that can be addressed and will enhance the efficiency of clinical research. The long-range goals are to develop networks that are based on common infrastructure elements, such as informatics, governance and common language.
Clinical Research Training
One of the most important factors determining the health and vitality of the clinical research enterprise is the scientific workforce. It is necessary to find ways to expand and diversify the clinical research workforce by optimising training and career development programmes for the many necessary players required to conduct successful clinical investigations.
These players include physicians, nurses, dieticians, epidemiologists, biostatisticians and informatics specialists. Tomorrow's clinician must be trained to work in the interdisciplinary, team-orientated environments that characterise today's emerging research efforts.
Ophthalmology residents should be trained in translational research and translational research projects. Visits of resident ophthalmologists or fellows at basic research centres should be encouraged or even financed. Similarly, visits of basic scientists to ophthalmic departments and eye hospitals should also be encouraged. The clinical research workforce must be large enough to catalyse the translation of discoveries during research to patient care at the community level. A major final goal is to extend these networking activities to affiliated centres in each EU region, thus contributing progressively to spreading harmonised information, governance, scientific language and training activities. This extension of networking in the different European regions will create a major organisation that will produce a volume of scientific response expected to compete favourably with any other region of the world and would certainly contribute to strengthen the EU health industry and innovation. n
Co-ordinating Infrastructure
